Axel Grothey, MD, West Cancer Center & Research Institute
Advertisement
Articles by Axel Grothey, MD, West Cancer Center & Research Institute
Advertisement
Latest Updated Articles
Role of I/O Combination Therapies in mCRCPublished: June 29th 2020 | Updated:
Later Lines of Therapy for mCRCPublished: June 29th 2020 | Updated:
Therapeutic Agents in Relapsed/Refractory mCRCPublished: June 29th 2020 | Updated:
Using I/O in MSI-H Tumors in mCRCPublished: June 29th 2020 | Updated:
Key Trials in mCRC: I/O Combination TherapiesPublished: June 29th 2020 | Updated:
Second-Line Treatment for mCRCPublished: June 29th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5